COVID-19 Update: Biogen is committed to continuing to provide support for our patients during these unprecedented times. Biogen Support Services is here to help your patients get started on treatment and provide additional support throughout their time on a Biogen therapy. For information about Biogen initiatives in response to the COVID-19 outbreak please visit Biogen COVID-19 Information Center.
FOR PATIENTS WITH RELAPSING FORMS OF MS
The efficacy of VUMERITY is based upon bioavailability studies
in patients with relapsing forms of multiple sclerosis and
healthy subjects comparing dimethyl fumarate to VUMERITY2
In Study 1 and Study 2 pivotal trials, dimethyl fumarate
demonstrated a 53% and 44% relative reduction in annualized
relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)2